CVS will cover Gilead hepatitis C treatment over new AbbVie drug: CNBC

(Reuters) - CVS Health Corp, one of the largest U.S. managers of drug benefits, said it would give the hepatitis C treatment from Gilead Sciences Inc preferred status and cover a new competing treatment from AbbVie Inc only as an exception, CNBC reported on Monday. Shares in Gilead rose nearly 3 percent after the report that CVS would favor the treatment, which can cost about $84,000, or $1,000 per pill. Its cost has spurred a national debate about whether drug prices had soared too high. ...



via Health News Headlines - Yahoo News http://ift.tt/1wd1VyP